Treatment response by ABX-CBL dose
| . | ABX-CBL dose group (mg/kg) . | All patients . | ||||
|---|---|---|---|---|---|---|
| 0.01 . | 0.1 . | 0.15 . | 0.2* . | 0.3* . | ||
| Enrolled | 9 | 7 | 5 | 36 | 2 | 59 |
| Analyzed for efficacy | 8 | 6 | 5 | 30 | 2 | 51 |
| Extended response | ||||||
| CR | 1 | 1 | 0 | 4 | 2 | 8 |
| PR | 1 | 2 | 2 | 8 | 0 | 13 |
| Best response | ||||||
| CR | 1 | 3 | 1 | 6 | 2 | 13 |
| PR | 2 | 1 | 1 | 9 | 0 | 13 |
| . | ABX-CBL dose group (mg/kg) . | All patients . | ||||
|---|---|---|---|---|---|---|
| 0.01 . | 0.1 . | 0.15 . | 0.2* . | 0.3* . | ||
| Enrolled | 9 | 7 | 5 | 36 | 2 | 59 |
| Analyzed for efficacy | 8 | 6 | 5 | 30 | 2 | 51 |
| Extended response | ||||||
| CR | 1 | 1 | 0 | 4 | 2 | 8 |
| PR | 1 | 2 | 2 | 8 | 0 | 13 |
| Best response | ||||||
| CR | 1 | 3 | 1 | 6 | 2 | 13 |
| PR | 2 | 1 | 1 | 9 | 0 | 13 |
One of the patients originally assigned to receive ABX-CBL at 0.3 mg/kg had severe myalgia and received all subsequent doses at 0.2 mg/kg and, therefore, was evaluated with the 0.2 mg/kg dose group for survival and response.